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conformational ﬂuctuations as a source of catalytic
defects in genetic diseases†
Julian E. Fuchs,a Ine´s G. Mun˜oz,b David J. Timsonc and Angel L. Pey*d
Theoretical and experimental evidence has shown that protein function, regulation and degradation
are intrinsically linked to the dynamic and ﬂuctuating nature of protein ensembles. However, the
eﬀect of missense mutations on catalytic performance are often interpreted from conformational
analyses derived from X-ray crystallography, molecular dynamics and modeling, while eﬀects on
conformational ﬂuctuations at the active site as the source of catalytic defects are rarely
investigated. Here, we explore the role of conformational ﬂuctuations in the catalytic eﬃciency of
WT and three missense mutations in the UDP-galactose 40-epimerase (GALE) protein causing type
III galactosemia. Using comprehensive molecular dynamics simulations and small angle X-ray
scattering we correlate low NAD+ binding aﬃnity in some mutants with an increased population of
non-competent conformations for NAD+ binding. Proteolysis studies combined with
thermodynamic calculations reveal that mutations aﬀecting GALE catalytic performance favor larger
conformational ﬂuctuations at the N-terminal domain and NAD+ binding site, shifting the
equilibrium towards non-binding competent states in the native ensemble. Therefore, we provide
a novel ensemble-based thermodynamic mechanism to explain catalytic defects caused by
missense mutations that links large and transient conformational ﬂuctuations and loss of catalytic
eﬃciency and substrate/coenzyme aﬃnity. In the context of this mechanism, we propose that
allosteric ligands aimed at modulating these transient conformational ﬂuctuations might correct
catalytic defects in inherited metabolic diseases, representing a diﬀerent approach to current small
ligand therapies which target the low stability, but not catalytic defects, of mutations.1. Introduction
Conformational uctuations are essential to understanding
protein function, regulation and degradation.1–4 Fluctuations
may be either local or involve large changes (unfolding) of
protein structure.1,5–8 Importantly, the role of dynamic alter-
ations in the pathogenic mechanisms of loss-of-function
genetic diseases, such as catalytic defects and protein misfold-
ing, are poorly understood. Catalytic defects are oen identied
experimentally by enzyme kinetic analyses and structurally
explained by the combination of X-ray diﬀraction crystal struc-
tures, molecular dynamics simulations and modelingical Chemistry, Faculty of Chemistry and
k, Austria
nit, Structural Biology and Biocomputing
rch Centre (CNIO), Madrid, Spain
ces, The University of Brighton, Brighton,
lty of Sciences, University of Granada,
tion (ESI) available. See DOI:
12procedures, oen providing a static view of the local structural
changes at the active sites to explain catalytic defects. Protein
destabilization and misfolding are customarily identied by in
vitro experiments such as thermal denaturation/inactivation
and proteolysis,9–14 and again, the destabilizing eﬀect can be
rationalized using structural information, as well as energy and
sequence-based algorithms.15–19 Novel therapies aimed at over-
coming destabilizing eﬀects of mutations using small ligands
(natural and pharmacological chaperones) are being
described.20–24
Despite the emergent importance of native state dynamics
on protein functionality, its role in mutation-associated cata-
lytic defects in inherited metabolic diseases has been largely
unexplored. Here, we investigate the relationship between
dynamic alterations and catalytic defects in three catalytic
mutations of UDP-galactose 40-epimerase (GALE, EC 5.1.3.2)
causing type III galactosemia. GALE catalyzes the interconver-
sion between UDP-galactose and UDP-glucose using NAD+ as
cofactor.25 Two common GALE disease-causing mutations
(p.N34S and p.G90E) decrease NAD+ binding aﬃnity, selectively
decrease protein unfolding cooperativity and facilitate proteo-
lytic cleavage at the loop formed by residues 34–45 near theThis journal is © The Royal Society of Chemistry 2016
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View Article OnlineNAD+ binding site.12 The impaired catalytic performance in
these two mutants may arise from structural uctuations of
the NAD+ binding site that energetically penalize coenzyme
binding. The p.V94M mutant greatly reduces GALE catalytic
eﬃciency,25,26 possibly due to binding of the substrate in
a non-competent fashion for catalysis,27 without largely
aﬀecting protein stability and exibility.12 We have combined
molecular dynamic (MD) simulations and small angle X-ray
scattering (SAXS) to ascertain the eﬀects of these mutations
on the native conformation and dynamics. Furthermore, we
have experimentally characterized the overall conformation
and relative population of partially unfolded states under
native conditions using partial proteolysis in combination
with thermodynamic analyses. Our results allow to propose
a thermodynamic mechanism that explains how mutational
defects on NAD+ binding occur due to an increment of the
population of non-competent binding states and changes in
their structure, and as result, allosteric ligands that bind to
and stabilize the N-terminal domain of GALE might be used
to overcome functional defects in type III galactosemia. We
propose that these results may generally apply to inherited
metabolic diseases in which point mutations, distant from
the enzyme active site, inuence binding or catalysis by
similar mechanisms.
2. Materials and methods
2.1. Molecular dynamics simulations
We performed molecular dynamics (MD) simulations of
wild-type and mutant GALE both in monomeric and dimeric
state, and in presence and absence of the NAD+ cofactor. In
total we performed 16 independent MD simulations of eight
monomeric and eight dimeric systems. For each assembly
state we investigated apo and NAD+-bound states of the wild-
type (WT) enzyme as well as the three mutants p.N34S,
p.G90E, and p.V94M. All simulations were based on a crystal
structure of GALE in complex with NAD+ (PDB:1EK5 28) that
was prepared for simulations using MOE's protonate3D and
mutate function.29
MD simulations were performed using the GPU code of
pmemd in Amber12.30 Amino acids were parameterized using
the Amber force eld 99SB with ILDN corrections,31 whilst the
NAD+ co-factors were described according to parameters from
Walker and Pavelites.32,33 We employed an extensive equilibra-
tion protocol34 before performing unrestrained sampling
simulations for 100 ns in NpT ensemble at 300 K and 1 bar. We
stored 1000 equal-spaced snapshots to trajectory for later
analysis. Shorter sampling periods (i.e. 10 ps) yielded essentially
the same results (data not shown).
We checked the simulations for energetic and structural
stability and found maximum Ca RMSD values to be below
3.5 A˚ over all 692 protein residues. Resulting conformational
ensembles were analyzed using ptraj and cpptraj from
AmberTools.35 We extracted residue-wise B-factors derived
from root mean squared uctuations of Ca atoms following
a global alignment. Additionally, we calculated thermody-
namic entropies from the distributions of protein backboneThis journal is © The Royal Society of Chemistry 2016torsion angles and summarized the three individual degrees
of freedom to residue-wise and total entropies.36 To study the
behavior of the 34–45 loop, we performed an alignment to the
whole respective protein subunits and recorded occurring
loop movements. Subsequently, we clustered the loop struc-
tures according to their Ca RMSD into two states using
a hierarchical agglomerative clustering approach. Respective
cluster centroids were extracted as representative structures
and compared in terms of structure and cluster occupancy.
Values for dimeric systems are reported as average over both
individual sub-units. Structures were visualized using
Pymol.37
2.2. Protein expression, purication and preparation
GALE enzymes were expressed and puried as described12 and
stored in HEPES (4-(2-hydroxyethyl)piperazine-1-ethanesulfonic
acid)–KOH 50 mM, 1 mM TCEP (Tris(2-carboxyethyl)phosphine
hydrochloride), pH 7.4. Thermolysin from Bacillus thermopro-
teolyticus Rokko was purchased from Sigma-Aldrich, exchanged
to (HEPES)–KOH 50 mM, CaCl2 100 mM, 1 mM TCEP, pH 7.4.
Proteins were ash frozen in liquid nitrogen and stored at
80 C. Protein concentration was measured spectrophoto-
metrically based on protein primary sequences.12
2.3. Small-angle X-ray scattering (SAXS)
Small-angle X-ray scattering (SAXS) measurements of wild-type
and p.G90E GALE mutant in solution were performed at
Diamond Light Source beamline B21 (Oxforshire, UK), using
a BioSAXS robot for sample loading from solutions of both
proteins at diﬀerent concentrations in 50 mM HEPES–KOH pH
7.4 and 1 mM TCEP at 277 K. During the experiment the
samples were exposed for 300 s in 10 s acquisition blocks using
a sample to detector distance of 3.9m and X-ray wavelength of 1 A˚.
The data were analyzed, buﬀer-subtracted, scaled, and merged
using the Scatter soware package (http://www.bioisis.net). This
soware was also used to check possible radiation damage of the
samples by visual inspection of the Guinier region as a function of
exposure time during data collection. RG and Dmax values were
calculated with PRIMUS and GNOM, and shape estimation was
carried out with DAMMIF/DAMMIN. Real-space scattering proles
of atomic models were calculated using CRYSOL and the nal
ab initio models were superimposed with the high-resolution
structure using the program SUPCOMB. The program
OLIGOMERwas used to calculate the ratio of the species present in
the solutions. All the SAXS programs are included in the ATSAS
programs package.38
2.4. Urea induced denaturation
Urea stock solutions were daily prepared in HEPES–KOH
50 mM, 1 mM TCEP, pH 7.4 at a 9 M concentration based on
refractive index measurements. GALE enzymes (5 mM in protein
monomer) were incubated in HEPES–KOH 50 mM, 1 mM TCEP,
pH 7.4, in the presence of urea (0–4 M) for 16 h at 25 C. Far-UV
CD spectra were acquired in a Jasco J-710 spectropolarimeter
using 1 mm path-length cuvettes at a 100 nm min1 scan rate
and 4 scans were registered and averaged.RSC Adv., 2016, 6, 58604–58612 | 58605
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View Article Online2.5. Proteolysis kinetics and thermodynamic analysis
GALE enzymes (20 mM in protein monomer) were incubated for
at least 6 h at 25 C in HEPES–KOH 50mM, 1mM TCEP, pH 7.4,
in the presence of urea (0–0.6 M), and in the absence or
presence of NAD+ 80 mM. Proteolysis was initiated by adding
thermolysin to a nal concentration of 0.1–0.6 mM. Aliquots
were withdrawn at diﬀerent times, and proteolysis was
quenched by adding EDTA (ethylenediaminetetraacetic acid)
pH 8 (to a 20 mM nal concentration) and mixed with an equal
volume of Laemmli's buﬀer. Control experiments without
thermolysin were prepared in the same way and used to
normalize the proteolysis kinetics. Proteolysis reactions were
evaluated using 12% acrylamide SDS-PAGE (sodium dodecyl
sulfate-polyacrylamide gel electrophoresis) and the bands
corresponding to full length GALE were scanned and analyzed
using the ImageJ soware (http://rsbweb.nih.gov/ij/).
The apparent rate constants for proteolysis (kp) were deter-
mined using a single exponental function. For the estimation of
equilibrium m values, kp was corrected for the inhibitory eﬀect
of urea on thermolysin degradation using the values previously
reported.39 The corrected rate constants (k0p) were used to
determine the equilibrium m values between the native and
cleavable state (X) by determining their urea concentration
dependence using the following equation:
ln k0p ¼ ln k0pð0 MÞ þ m
RT
½urea (1)
where R is the ideal gas constant (1.987 cal mol1 K1) and T is
the absolute temperature (298.15 K). The theoretical equilib-
rium m value for the global unfolding of GALE monomers was
determined using the correlations from.40
To estimate the eﬀect of mutations on the thermodynamic
stability of the native vs. the cleavable state, we have
assumed that mutations do not aﬀect the intrinsic proteolytic
step (X/ F), and thus, changes in the overall proteolysis rate
aer normalization using protease concentration (kWT and kmut)
reect changes in the equilibrium constant between N and X
(N 4 X;41), and therefore in their free energy changes (DDG),
following eqn (2):
DDGmut–WT ¼ RT ln(kmut/kWT) (2)3. Results
3.1. Molecular dynamics (MD) simulations identify changes
in conformational states in the native ensemble due to
catalytic GALE mutations
GALE disease-associated variants aﬀect catalytic properties and
binding of NAD+ increasing proteolysis susceptibility.12,25,26,42–44
Indeed, based on proteolysis sensitivity measurements and the
crystal structure of GALE,12 we have proposed that certain
catalytic mutations (e.g. p.N34S and p.G90E) could aﬀect the
local exibility of the loop 34–45, which encloses the NAD+
binding site. Knowing that p.G90E and p.V94M present only
0.1% and 3% respectively of the wild-type catalytic activity, and58606 | RSC Adv., 2016, 6, 58604–58612p.N34S shows 4-fold lower aﬃnity for NAD+ which is abolished
in p.G90E, we hypothesize that the catalytic defects and NAD+
binding eﬀects could be associated with conformational
changes arising from dynamic alterations in the native state
ensemble.
MD simulations were used to characterize the conforma-
tional microstates present in native GALE ensembles at
atomic resolution. GALE monomeric enzymes are rather
unstable over 100 ns simulation time, and therefore, subse-
quent analyses were carried out using the functional GALE
dimer only. We have focused our analyses on the 34–45 loop
where major conformational transitions are found (reaching
RMSD values up to 8 A˚ in apo GALE systems; see Fig. S1† for
a 2D RMSD plot). By contrast, NAD+-bound GALE complexes
show drastically reduced loop mobility (Fig. S1†), supporting
its stabilizing eﬀect towards proteolysis.12 The aggregate
simulation time of 1.6 ms of the dimer (i.e. 3.2 ms sampling
time for individual loops) make us condent on the observed
trends for loop dynamics, despite individual simulation
(100 ns) is at the lower limit for investigating changes in loop
movements.45 In this regard, enhanced sampling methods46
could be helpful to provide further insight into the loop
trends described here.
We performed a cluster analysis to investigate plausible loop
conformations during molecular dynamics simulations
(Fig. 1A–D). MD trajectories were clustered into two states: the
major one representing a ground state (close to that of the
crystal structure) and the minor excited (i.e. high-energy) state.
The relative populations of the major and minor states depend
on the cut-oﬀ values used in the clustering procedure, even
though the qualitative trends described here for the eﬀect of
mutations and NAD+ binding are robust.
In the absence of NAD+, the minor conformation is more
populated in the p.N34S and p.G90Emutants (Fig. 1E), defective
in NAD+ binding, while generally the thermolysin cleavage site
Ala38–Phe39 is more solvent exposed in these high-energy
states (Fig. 1A and C). In the presence of NAD+, a much lower
population of the high-energy states is found, except for p.V94M
(Fig. 1E), an in all cases the conformation of the ground and
excited states is more similar (Fig. 1B and D). These analyses
support that two conformational states exist in equilibrium in
the absence of NAD+, with the more populated displaying
higher aﬃnity for NAD+ due to higher structural complemen-
tarity that likely prevents from thermolysin cleavage (Fig. 1A–D).
Therefore, the lower aﬃnity for NAD+ in p.N34S and the
inability of p.G90E to bind it, can be partly explained by a shi
in the conformational equilibrium towards non-binding
competent states, remodeling the protein energy landscape in
such a way that cofactor binding is thermodynamically
penalized.4,47
According to this proposed mechanism, p.N34S and
p.G90E could be more susceptible to proteolytic attack at the
34–45 loop since they increase the population of cleavable
(excited) non-binding competent states, while NAD+ binding
reduces the population of cleavable states explaining its
protective eﬀect.12 Alternatively, accelerated proteolysis and
low binding aﬃnity could also be explained by enhancementThis journal is © The Royal Society of Chemistry 2016
Fig. 1 Molecular dynamics simulations reveal conformational heterogeneity in GALE. (A–D) Characterization of two alternative conformations of
the loop 34–45 from a two-state clustering of MD trajectories. The major conformations (ground states) of the 34–45 loop (shown as cartoon
and lines) are colored in black and minor conformations (excited states) in white. The NAD+ cofactor is shown in stick representation where
present and the thermolysin cleavage site in the loop is indicated as a white sphere. Cluster analyses correspond toWTGALEwithout (A) and with
NAD+ (B) and p.G90E without (C) and with NAD+ (D). (E) Population of excited states in the absence and presence of NAD+ from representative
cluster analyses. (F) Changes in local dynamics (B-factors) around the thermolysin cleavage site (loop 34–45) in the absence (left panel) or the
presence of NAD+ (right panel).
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View Article Onlineof local dynamics at the NAD+ binding site that impedes its
correct spatial complementarity towards the cofactor. To
distinguish between these two mechanisms, we have
analyzed local dynamics at the residue level by MD simula-
tions (Fig. 1F). Interestingly, we nd that the exibility
around the cleavage site (loop 34–45) does not correlate with
the experimentally determined proteolysis susceptibility
(Fig. 1F and ref. 12), implying that proteolysis susceptibility
is not directly linked to local dynamics in this case. Addi-
tionally, p.N34S and p.G90E facilitate thermally induced
partial unfolding12 which supports a population-shi mech-
anism. Addition of NAD+ decreases the local dynamics
around the cleavage site, which likely reects the shi
towards binding competent states (Fig. 1E).3.2. Conformation of WT and p.G90E in solution studied by
small-angle X-ray scattering (SAXS)
To investigate experimentally the eﬀect of a catalytic mutation
on GALE conformational ensemble, we have determined the
low-resolution conformation of WT and p.G90E by SAXS. The
overall parameters for SAXS modeling are summarized in
Table S1.† Scattering proles of both proteins show diﬀerences
in the radius of gyration calculated both in real and reciprocalThis journal is © The Royal Society of Chemistry 2016space, as well as in their corresponding Dmax values, and Kratky
plots suggested an increase in the exibility in the p.G90E
mutant (Fig. 2A–D). Envelope reconstruction clearly results in
a more elongated shape of the p.G90E mutant than the WT
protein (Fig. 2E and F). The ab initio shape reconstructions
superimposed well with the available crystallographic data (PDB
entry 1EK6), but exhibited a molecular envelope larger than that
observed in the crystal structure, especially in the p.G90E
mutant.
In combination with our results using MD simulations
(Fig. 1), these SAXS analyses support the existence of confor-
mational uctuations (i.e. high-energy states) in GALE in solu-
tion, which are enhanced by the p.G90E mutation.3.3. Thermodynamic characterization of high-energy states
under native conditions by proteolysis
We have used proteolysis to evaluate the eﬀect of GALE muta-
tions on the energetics of the native state ensemble, particularly
on high-energy excited (cleavable) states, such as those detected
by MD simulations and diﬃcult to characterize experimentally.
Proteolysis of GALE under native conditions is well-described by
the following mechanism: N5 X0 F, where X is the cleavable
state in equilibrium with the native state (N), and undergoesRSC Adv., 2016, 6, 58604–58612 | 58607
Fig. 2 Structural models of GALE WT and p.G90E in solution by SAXS. (A and B) Experimental scattering curves (dots) and calculated (lines) SAXS
data for GALE WT (A) and p.G90E (B) at diﬀerent protein concentrations. (C and D) P(r) functions for GALE WT (C) and p.G90E (D). The tail reveals
themore elongated dimer shape of the p.G90Emutant. (E and F) Ab initio shape reconstructions of GALEWT and p.G90Ewere superimposed on
the crystal structure (PDB entry 1EK6).
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View Article Onlineproteolytic cleavage to produce a proteolyzed state F. The step N
4 X is governed by a equilibrium constant K, while the step
X/ F is determined by an intrinsic proteolysis rate constant
k. To provide insight into the conformation of X, we have
measured proteolysis kinetics in the presence of low urea
concentrations. Urea and protease concentrations were kept
very low to minimize deviations from native conditions
(Fig. S2†) and to ensure that the proteolysis step X / F is
rate-limiting, and thus, the overall proteolysis rate constant
kp z Kk.8,41,48 Experimental kp values (Fig. 3A–D) were deter-
mined from rst-order kinetic decays (Fig. S3†). Based on this
mechanism, and upon correction of kp values due to modest
inhibition caused by urea,39 changes in proteolysis kinetics
were used to determine equilibrium m values using eqn (1)
(Fig. 3E–H). These equilibrium m values (Fig. 3I) are
proportional to the magnitude of the conformational change
between native and cleavable states (Fig. 3J; i.e. degree of
unfolding), and thus provide structural information on the
cleavable state X.
The sensitivity to thermolysin degradation correlates well
with the eﬀect of urea on proteolysis kinetics (Fig. 3I–K): the
higher the sensitivity to proteolysis of a GALE variant, the
higher the eﬀect of urea. For WT and p.V94M, we found fairly
similar equilibrium m values, on average a 0.55 kcal mol1 M1,
which implies that 15% of the native structure (50 residues)
is unfolded in the cleavable state X (Fig. 3J). In the case of
p.N34S and p.G90E, the equilibrium m value is around
1.4 kcal mol1 M1, and thus, about 40% of the native
structure (130 residues) is unfolded in the cleavable state for58608 | RSC Adv., 2016, 6, 58604–58612these two mutants. Therefore, p.N34S and p.G90E populate
a more extensively unfolded cleavable state under native
conditions, and since proteolysis occur at Ala38–Phe39,12 likely
involves the N-terminal domain that contains the NAD+ binding
site. Moreover, a direct comparison of proteolysis rate constants
normalized by protease concentration provides ameasure of the
thermodynamic destabilization induced by p.N34S and p.G90E
on the N 4 X equilibrium (eqn (2)), which amounts to
1.5–2 kcal mol1, while the eﬀect of p.V94M is marginal
(Fig. 3K). These results show that p.N34S and p.G90E shi the
N4 X towards the cleavable state by a factor of 22.5  4.5 and
14.1  3.1. Overall, in the context of the population-shi
mechanism, the lower aﬃnity for NAD+ in p.N34S and p.G90E
is explained by the stabilization of non-competent
binding states and changes in their structure under native
conditions.
Addition of NAD+ has a stabilizing eﬀect towards prote-
olysis (Fig. 3 and S3†), although this eﬀect is variant-
dependent. In p.G90E, only a 20% decrease in the
proteolysis rate constant is found, while this eﬀect is of 40%
in WT, 60% in p.N34S and 130% in p.V94M. The stabilization
agrees well with their corresponding aﬃnities for NAD+.12
Importantly, the stabilization exerted by NAD+ does not cause
large changes in the equilibriumm values (Fig. 3I), indicating
that NAD+ binding does not alter the structure of the cleav-
able state but instead simply shis the conformational
equilibrium towards more protease-resistant NAD+ binding
competent states.This journal is © The Royal Society of Chemistry 2016
Fig. 3 Urea dependence of proteolysis rate constants and thermodynamic analysis. (A–D) proteolysis rate constants (kp) at diﬀerent urea
concentrations in the absence or presence of NAD+; (E–H) corrected proteolysis rate constants (k0p) by urea inhibition of thermolysin as reported
by ref. 39. The slopes of these plots are used to determined equilibrium m values. (I and J) Equilibrium m values (I) for the native-to-cleavable
state (X) equilibrium determined by proteolysis and the corresponding fraction of accessible surface area (ASA) unfolded in the X state (J). (K)
Eﬀect of mutations on the change in free energy (DDG(mut–WT)) between native and cleavable states. Error bars are ﬁtting errors or those
propagated from them.
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View Article Online4. Discussion
Inherited metabolic diseases are oen caused by missense
mutations impairing enzyme activity, regulatory properties
and/or intracellular stability.21,24,49–53 Two of the most common
pathogenic mechanisms either involve native state destabili-
zation or catalytic alterations, which are customarily consid-
ered as separate mechanisms. Here we explore the possibilityThis journal is © The Royal Society of Chemistry 2016of a relationship between these two mechanisms, by
describing how two mutations in GALE associated to type III
galactosemia aﬀect the aﬃnity for NAD+, and therefore their
catalytic performance, promoting unfolding of the N-terminal
domain and NAD+ binding site. We identify alterations in the
conformational ensemble of p.N34S and p.G90E consistent
with a shi in the conformational equilibrium towards
partially unfolded non-competent states for NAD+ binding asRSC Adv., 2016, 6, 58604–58612 | 58609
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View Article Onlineshown by a combination of proteolysis and SAXS experiments
and MD simulations. Therefore, we provide experimental and
computational evidence to support an ensemble-based
mechanism to explain catalytic mutations, in which struc-
tural and chemical perturbations caused by the mutations
shi the equilibrium towards inactive conformations in the
native state ensemble.
It must be noted that conformational uctuations at the
NAD+ binding site occur even in GALE variants with WT-like
binding aﬃnity (Fig. 1 and 3). Non-binding competent
excited states can be used by nature to provide the appropriate
binding aﬃnity for enzyme function at physiologically rele-
vant ligand concentrations, allowing conformational excur-
sions to states with diﬀerent degrees of unfolding.6,47 In this
context, p.N34S and p.G90E are deleterious because they shi
the conformational equilibrium towards more unstructured
partially unfolded conformations in the native state ensemble
thus energetically penalizing NAD+ binding (Fig. 4A and B).
These excited states seem to be populated to signicant levels,
as seen by the ability of our MD simulations to detect them
even at the low microsecond sampling time scale (Fig. 1),
although variants with low binding aﬃnity for NAD+ clearly
promote the population of excited states. This population-
shi is reected in our SAXS analyses as an expansion in
the average ensemble in solution (Fig. 2), thus overall sup-
porting this conformational-selection mechanism for the
binding of NAD+ to GALE. In addition, proteolysis experimentFig. 4 Pictorial representation of the eﬀect of catalytic mutations on
the structure of excited states and NAD+ binding aﬃnity and its
potential correction by allosteric eﬀectors. Panels (A) and (B) show the
equilibrium between native GALE WT (A) and p.G90E (B) and the
excited, cleavable states as inferred from native proteolysis experi-
ments. In panel (C), the potential eﬀect of an allosteric ligand binding
to an unstructured region of the excited state of a catalytic mutant
leading to correction of its NAD+ binding aﬃnity by a coupled binding-
folding process. For sake of simplicity, only the GALE monomer is
displayed (based on PDB:1EK5).
58610 | RSC Adv., 2016, 6, 58604–58612revealed an increase in population of these excited states in
p.N34S and p.G90E as well as a change in their overall
structure, showing a higher degree of unfolding (Fig. 3).
Importantly, since the population of these excited states is
inversely proportional to NAD+ binding aﬃnity, it is plausible
that allosteric eﬀectors would be able to bind to WT-like
excited states destabilized by catalytic mutations such as
p.N34S and p.G90E, thus partially restoring the binding
aﬃnity for NAD+ (Fig. 4C).
So far, we have identied a thermodynamic signature for
mutations aﬀecting NAD+ binding to GALE. Consistently, this
signature is not found in p.V94M, a mutant strongly reducing
catalytic eﬃciency with mild eﬀects on the apparent aﬃnities
for the substrate and cofactor.12,25 Previous MD simulations
have suggested little eﬀect of p.V94M on the interaction with
substrate and cofactor.27 However, p.V94M seems to severely
aﬀect the ability of GALE active site to bring together the NAD+
cofactor, the substrate and the catalytic Tyr157, leading to
non-optimal ternary complex for catalysis.25 In the case of
p.N34S and p.G90E, their low binding aﬃnity for NAD+ (Fig. 4
and ref. 12) is caused by a shi in the conformational equi-
librium of the apo-state towards NAD+ non-binding competent
states, and in addition, p.G90E could develop unfavorable
electrostatic interactions that may also contribute to its
apparent inability to bind the cofactor and its dramatically low
activity.12,255. Conclusions
In conclusion, we describe a computational and experimental
approach that directly links mutational eﬀects on native state
uctuations to catalytic and coenzyme binding defects in an
inherited metabolic disease. We propose that our strategy, in the
context of an ensemble-based mechanism, would be helpful to
understand better mutational eﬀects on catalysis and regulation
(such as allostery and cooperativity), which are frequently altered
in inborn errors of metabolism such as phenylketonuria,10,50,54
classical homocystinuria,13,55 inherited galactosemias25,56 and
primary hyperoxaluria type I.49 Interestingly, several previous
works allow to propose some correlation between altered proteo-
lytic susceptibility and allosteric response in inborn errors of
metabolism,10,13,57 but not for catalytic alterations. Therefore, we
advance the general hypothesis that disease-associated point
mutations oen adversely disturb native-state dynamics. More
generally, we expect that future work with mutations associated to
other metabolic diseases will test whether our ensemble-based
mechanism provides a unifying framework to reconcile analysis
from enzyme kinetic and ligand binding studies, X-ray crystal
structures, extensive molecular dynamic simulations and experi-
mental ensemble studies using techniques such as SAXS and
proteolysis. From a therapeutic viewpoint, we propose a strategy
aimed at identifying molecules which can (partially) reverse the
changes in active-site conformational uctuations upon binding to
cryptic allosteric sites (Fig. 4), alternative to current approaches
that focus on compounds which promote proper folding of
aﬀected proteins.This journal is © The Royal Society of Chemistry 2016
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